IP Library Granted Patent US 12,486,242
Granted Patent B2
US 12,486,242 · App. 17/918,671 · Granted Dec 2, 2025

Long-acting low-addiction HNK derivative and preparation method therefor

Inventors: Shu Peng Li (Oakville, CA); Qiang Zhou (San Francisco, CA)
Assignee: SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD.
C07D307/68A61P25/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,486,242
App. No.
17/918,671
Granted
Dec 2, 2025
Kind
B2
Abstract

The present application relates to a compound having the functions of being an antidepressant, improving anxiety and post-traumatic stress syndrome, anesthetizing, easing pain, improving cognitive function, protecting the lungs, preventing or treating amyotrophic lateral sclerosis or preventing or treating complex regional pain syndrome. Compared with existing known HNK compounds, the compound of the present invention has a longer drug efficacy period, and the compound of the present invention essentially does not lead to addiction.

Claims (24)

1 . A compound represented by Formula III, or a salt, stereoisomer or tautomer thereof:

wherein,

m is an integer from 0 to 3, n is an integer from 0 to 4, and p is an integer from 0 to 3;

R 1 and R 2 are each independently one or more selected from a group consisting of H, halogen, hydroxyl, amino, cyano, substituted or unsubstituted C 1 -C 6 alkyl group, substituted or unsubstituted C 2 -C 6 alkenyl group, substituted or unsubstituted C 2 -C 6 alkynyl group, substituted or unsubstituted C 3 -C 10 cycloalkyl group, substituted or unsubstituted C 2 -C 10 heterocyclic group, substituted or unsubstituted C 1 -C 6 alkoxy group, substituted or unsubstituted mono- and di-C 1 -C 6 alkylamino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heteroaryl group;

R 3 is halogen;

R 4 is selected from a group consisting of H, substituted or unsubstituted C 1 -C 6 alkyl group, substituted or unsubstituted C 1 -C 8 acyl group, substituted or unsubstituted arylacyl group, and substituted or unsubstituted heteroarylacyl group;

R 6 is selected from a group consisting of H, substituted or unsubstituted C 1 -C 6 alkyl group, substituted or unsubstituted C 2 -C 6 alkenyl group, substituted or unsubstituted C 2 -C 6 alkynyl group, substituted or unsubstituted C 3 -C 10 cycloalkyl group, substituted or unsubstituted C 2 -C 10 heterocyclic group, substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, substituted or unsubstituted C 1 -C 8 acyl group, substituted or unsubstituted arylacyl group, and substituted or unsubstituted heteroaryl acyl,

wherein a group is substituted means that the group is substituted by a substituent selected from OH; NH 2 ; C 1 -C 10 alkyl, alkenyl or alkynyl group; C 1 -C 10 alkylamine group; sulfhydryl group; C 1 -C 10 alkylsulfhydryl group; C 1 -C 20 alkoxy group; C 1 -C 10 carbonyl group; C 3 -C 10 cycloalkyl group; 3 to 10-membered heterocyclic group with one or more heteroatoms selected from N, S, O and P; C 6 -C 20 aryl group; C 2 -C 20 heteroaryl group; nitrocyano; and halogen.

2 . The compound according to claim 1 , represented by Formula IV:

3 . The compound according to claim 1 , wherein the compound is shown below:

4 . The compound according to claim 1 , wherein the compound is shown below:

5 . A compound, or a salt, stereoisomer or tautomer thereof, wherein the compound is shown below:

wherein Ry is H or a protecting group.

6 . The compound according to claim 5 , wherein the compound is shown below:

7 . The compound according to claim 5 , wherein the compound is shown below:

8 . A pharmaceutical composition, comprising the compound, or the salt, stereoisomer or tautomer thereof according to claim 1 , and optionally a pharmaceutically acceptable carrier.

9 . A pharmaceutical composition, comprising the compound, or the salt, stereoisomer or tautomer thereof according to claim 5 , and optionally a pharmaceutically acceptable carrier.

10 . A preparation method of a compound (I 6 ), wherein the preparation method comprises steps of:

esterifying a compound (G) to produce product (H 6 ); and

deprotecting the product (H 6 ) to produce the compound (I 6 ),

11 . A method for anesthesia, alleviating pain, improving cognitive function, lung protection, anti-depression, mitigating anxiety and post-traumatic stress syndrome, or preventing or treating amyotrophic lateral sclerosis or complex regional pain syndrome of a subject, comprising administrating a therapeutic effective amount of the compound, or the salt, stereoisomer or tautomer thereof according to claim 1 to the subject.

12 . The method of claim 11 , wherein the pain comprises chronic pain or neuropathic pain; depression comprises bipolar depression or major depressive disorder; and improving the cognitive function comprises preventing or treating Alzheimer's dementia or Parkinson's disease.

13 . A method for anesthesia, alleviating pain, improving cognitive function, lung protection, anti-depression, mitigating anxiety and post-traumatic stress syndrome, or preventing or treating amyotrophic lateral sclerosis or complex regional pain syndrome of a subject, comprising administrating a therapeutic effective amount of the compound, or the salt, stereoisomer or tautomer thereof according to claim 5 to the subject.

14 . The method of claim 13 , wherein the pain comprises chronic pain or neuropathic pain; depression comprises bipolar depression or major depressive disorder; and improving the cognitive function comprises preventing or treating Alzheimer's dementia or Parkinson's disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2026
From: SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD.
To: HANGZHOU RUIXI BIOSCIENCE TECHNOLOGY LIMITED COMPANY
Reel/Frame 075542/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2022
From: LI, SHU PENG; ZHOU, QIANG
To: SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD
Reel/Frame 062249/0164 →
Continuity (1)
Related Publication 20230312500A1 · Oct 5, 2023
References Cited (40)
US 9650352B2 · Wainer · 2017 [cited by examiner]
US 9867830B2 · Wainer · 2018 [cited by applicant]
US 9963435B2 · Gomez · 2018 [cited by applicant]
US 10738018B2 · Gomez · 2020 [cited by applicant]
US 10919842B2 · Thomas · 2021 [cited by applicant]
US 20140296241A1 · Wainer et al. · 2014 [cited by applicant]
US 20170049780A1 · Wainer et al. · 2017 [cited by applicant]
US 20180057470A1 · Gomez et al. · 2018 [cited by applicant]
US 20180098993A1 · Wainer et al. · 2018 [cited by applicant]
US 20180251435A1 · Gomez et al. · 2018 [cited by applicant]
US 20190135732A1 · Thomas et al. · 2019 [cited by applicant]
US 20190240184A1 · Hashimoto · 2019 [cited by applicant]
US 20200360393A1 · Wainer et al. · 2020 [cited by applicant]
US 20210139411A1 · Thomas · 2021 [cited by applicant]
US 20230192594A1 · Thomas · 2023 [cited by applicant]
CN 104395283A · 2015 [cited by applicant]
CN 109311801A · 2019 [cited by applicant]
CN 109475514A · 2019 [cited by applicant]
CN 110167541A · 2019 [cited by applicant]
CN 110218157A · 2019 [cited by applicant]
CN 110559282A · 2019 [cited by applicant]
JP 2015501302A · 2015 [cited by applicant]
JP 2019510768A · 2019 [cited by applicant]
WO 2013056229A1 · 2013 [cited by applicant]
WO 2017165878A1 · 2017 [cited by applicant]
WO 2018079693A1 · 2018 [cited by applicant]
WO 2019169165A1 · 2019 [cited by applicant]
WO 2022041172A1 · 2022 [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112360, mailed on Jun. 16, 2021, 3 pages. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112360, mailed on Jun. 16, 2021, 3 pages. [cited by applicant]
C. G. Wermuth, “The Practice of Medicinal Chemistry”, Telecommunication company, Aug. 15, 1998, p. 235-271, Chapter XIII, 39 pages. [cited by applicant]
Nozaki masakatsu, et al.,“The Practice of Medicinal Chemistry”, Chemical company, 1st edition, Jul. 1, 1995, p. 98-99. [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112363, mailed on Jun. 2, 2021, 3 pages. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112363, mailed on Jun. 2, 2021, 3 pages. [cited by applicant]
Supplementary European Search Report in the European application No. 20950843.1, mailed on Aug. 14, 2023, 7 pages. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112376, mailed on Jun. 2, 2021, 3 pages. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112373, mailed on Jun. 8, 2021, 10 pages. [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112373, mailed on Jun. 8, 2021. [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112376, mailed on Jun. 2, 2021. [cited by applicant]
Patrick J. Morris et al. “Synthesis and N-Methyl-D-aspartate (NMDA) Receptor Activity of Ketamine Metabolites” Letter, vol. 19, Aug. 22, 2017 (Aug. 22, 2017). [cited by applicant]